doi: 10.1086/526775.
Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline
Affiliations
- PMID: 18199038
- DOI: 10.1086/526775
Item in Clipboard
Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline
Clin Infect Dis.
.
Abstract
Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase- and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.
Comment in
-
Tigecycline for Acinetobacter baumannii infection: other considerations.Clin Infect Dis. 2008 Jun 1;46(11):1797-8; author reply 1798-9. doi: 10.1086/588051. Clin Infect Dis. 2008. PMID: 18462123 No abstract available.
-
Correction of a reference to clinical laboratory standards institute interpretive criteria.Clin Infect Dis. 2008 Jun 1;46(11):1798; author reply 1798-9. doi: 10.1086/588056. Clin Infect Dis. 2008. PMID: 18462124 No abstract available.
-
Multidrug-resistant Klebsiella pneumoniae mediastinitis safely and effectively treated with prolonged administration of tigecycline.Clin Infect Dis. 2008 Jun 15;46(12):1932-3. doi: 10.1086/588557. Clin Infect Dis. 2008. PMID: 18540810 No abstract available.
Similar articles
-
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40. doi: 10.1093/jac/dkn249. J Antimicrob Chemother. 2008. PMID: 18684704 Clinical Trial.
-
Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.Int J Antimicrob Agents. 2014 Aug;44(2):112-6. doi: 10.1016/j.ijantimicag.2014.04.014. Epub 2014 Jun 2. Int J Antimicrob Agents. 2014. PMID: 25059444
-
Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.Clin Ther. 2012 Jan;34(1):124-37. doi: 10.1016/j.clinthera.2011.11.023. Epub 2011 Dec 9. Clin Ther. 2012. PMID: 22154196
-
The current state of multidrug-resistant gram-negative bacilli in North America.Pharmacotherapy. 2008 Feb;28(2):235-49. doi: 10.1592/phco.28.2.235. Pharmacotherapy. 2008. PMID: 18225969 Review.
-
Multidrug-resistant Gram-negative infections: what are the treatment options?Drugs. 2009 Oct 1;69(14):1879-901. doi: 10.2165/11315690-000000000-00000. Drugs. 2009. PMID: 19747006 Review.
Cited by
-
Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient.Ann Saudi Med. 2010 Sep-Oct;30(5):404-7. doi: 10.4103/0256-4947.67087. Ann Saudi Med. 2010. PMID: 20697161 Free PMC article.
-
Calculated parenteral initial treatment of bacterial infections: Microbiology.GMS Infect Dis. 2020 Mar 26;8:Doc18. doi: 10.3205/id000062. eCollection 2020. GMS Infect Dis. 2020. PMID: 32373443 Free PMC article.
-
Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.Drugs. 2014 Aug;74(12):1315-33. doi: 10.1007/s40265-014-0267-8. Drugs. 2014. PMID: 25091170 Free PMC article. Review.
-
Advances in MRSA drug discovery: where are we and where do we need to be?Expert Opin Drug Discov. 2013 Sep;8(9):1095-116. doi: 10.1517/17460441.2013.807246. Epub 2013 Jul 6. Expert Opin Drug Discov. 2013. PMID: 23829425 Free PMC article. Review.
-
Low levels of tetracyclines select for a mutation that prevents the evolution of high-level resistance to tigecycline.PLoS Biol. 2022 Sep 28;20(9):e3001808. doi: 10.1371/journal.pbio.3001808. eCollection 2022 Sep. PLoS Biol. 2022. PMID: 36170241 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
